Lysandropoulos A - Search Results

1

Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 α-chain (CD11a) in MS patients.

Jilek S, Mathias A, Canales M, Lysandropoulos A, Pantaleo G, Schluep M, Du Pasquier RA. Jilek S, et al. Among authors: lysandropoulos a. Mult Scler. 2014 Jun;20(7):837-42. doi: 10.1177/1352458513513208. Epub 2013 Nov 20. Mult Scler. 2014. PMID: 24258149

2

Vitamin D has a direct immunomodulatory effect on CD8+ T cells of patients with early multiple sclerosis and healthy control subjects.

Lysandropoulos AP, Jaquiéry E, Jilek S, Pantaleo G, Schluep M, Du Pasquier RA. Lysandropoulos AP, et al. J Neuroimmunol. 2011 Apr;233(1-2):240-4. doi: 10.1016/j.jneuroim.2010.11.008. Epub 2010 Dec 24. J Neuroimmunol. 2011. PMID: 21186064

3

Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.

Jilek S, Jaquiéry E, Hirsch HH, Lysandropoulos A, Canales M, Guignard L, Schluep M, Pantaleo G, Du Pasquier RA. Jilek S, et al. Among authors: lysandropoulos a. Lancet Neurol. 2010 Mar;9(3):264-72. doi: 10.1016/S1474-4422(10)70006-5. Epub 2010 Jan 29. Lancet Neurol. 2010. PMID: 20117055 Free article.

4

Demyelination as a complication of new immunomodulatory treatments.

Lysandropoulos AP, Du Pasquier RA. Lysandropoulos AP, et al. Curr Opin Neurol. 2010 Jun;23(3):226-33. doi: 10.1097/WCO.0b013e3283398c96. Curr Opin Neurol. 2010. PMID: 20442571 Review.

5

Intrathecal immune responses to EBV in early MS.

Jaquiéry E, Jilek S, Schluep M, Meylan P, Lysandropoulos A, Pantaleo G, Du Pasquier RA. Jaquiéry E, et al. Among authors: lysandropoulos a. Eur J Immunol. 2010 Mar;40(3):878-87. doi: 10.1002/eji.200939761. Eur J Immunol. 2010. PMID: 20017197 Free article.

6

HLA-B7-restricted EBV-specific CD8+ T cells are dysregulated in multiple sclerosis.

Jilek S, Schluep M, Harari A, Canales M, Lysandropoulos A, Zekeridou A, Pantaleo G, Du Pasquier RA. Jilek S, et al. Among authors: lysandropoulos a. J Immunol. 2012 May 1;188(9):4671-80. doi: 10.4049/jimmunol.1103100. Epub 2012 Mar 28. J Immunol. 2012. PMID: 22461701 Free article. Clinical Trial.

7

Human Leukocyte Antigen Genotype as a Marker of Multiple Sclerosis Prognosis.

Lysandropoulos AP, Perrotta G, Billiet T, Ribbens A, Du Pasquier R, Pot Kreis C, Maggi P, Théaudin M. Lysandropoulos AP, et al. Can J Neurol Sci. 2020 Mar;47(2):189-196. doi: 10.1017/cjn.2019.329. Can J Neurol Sci. 2020. PMID: 31787121

8

Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.

N'gbo N'gbo Ikazabo R, Mostosi C, Quivron B, Delberghe X, El Hafsi K, Lysandropoulos AP. N'gbo N'gbo Ikazabo R, et al. Clin Ther. 2016 Mar;38(3):670-5. doi: 10.1016/j.clinthera.2016.01.010. Epub 2016 Feb 5. Clin Ther. 2016. PMID: 26856928

9

Severe auto-immune hemolytic anemia in a fingolimod-treated multiple sclerosis patient.

Lysandropoulos AP, Benghiat F. Lysandropoulos AP, et al. Mult Scler. 2013 Oct;19(11):1551-2. doi: 10.1177/1352458513493035. Epub 2013 Jul 1. Mult Scler. 2013. PMID: 23817558 No abstract available.

10

Improving fatigue in multiple sclerosis by smartphone-supported energy management: The MS TeleCoach feasibility study.

D'hooghe M, Van Gassen G, Kos D, Bouquiaux O, Cambron M, Decoo D, Lysandropoulos A, Van Wijmeersch B, Willekens B, Penner IK, Nagels G. D'hooghe M, et al. Among authors: lysandropoulos a. Mult Scler Relat Disord. 2018 May;22:90-96. doi: 10.1016/j.msard.2018.03.020. Epub 2018 Mar 27. Mult Scler Relat Disord. 2018. PMID: 29649789 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39 results

Search Page

Filters